

Dr. Hartmut J. Ehrlich

Vice President, Global Research and Development Baxter BioScience

Dr. Hartmut Ehrlich is a physician with over 20 years experience in biopharmaceutical research and product development. He graduated from Medical School at the University of Giessen, Germany in 1985 and completed his Doctorate at the Clinical Research Unit for Blood Coagulation and Thrombosis of the Max-Planck-Foundation. Subsequently, he spent over 6 years in basic research and patient care at the Department of Medicine, Hematology-Oncology of Indiana University and the Lilly Laboratories for Clinical Research in Indianapolis, Indiana, the Department of Molecular Biology at the Central Laboratory of the Dutch Red Cross in Amsterdam, The Netherlands, and the Kerckhoff-Clinic of the Max-Planck-Foundation in Bad Nauheim, Germany.



In 1991, Dr. Ehrlich joined Sandoz, now Novartis, and spent almost 4 years in clinical development as well as corporate project management in immunology-oncology in Nuremberg, Germany and Basel, Switzerland.

Dr. Ehrlich joined Baxter in 1995 as Medical Director for its former Biotech business, and held several positions of increasing responsibility until September 2003 when he was named Vice President, Global Clinical R&D for the BioScience Division. In September of 2006, he was promoted to his current position, leading all R&D efforts for BioScience.

During his career, Dr. Ehrlich has authored and co-authored well over 100 scientific publications and book chapters. He has been lecturing in several university programs in Austria and abroad, and he is on the Advisory Board for the Biotec MBA program at Danube University in Krems/Austria. Most importantly, he was associated with the successful development and licensure of numerous biotechnological products in the areas of hematology – oncology, immunology, critical care, hemophilia, vaccines and biosurgery.